Hims & Hers Health Stock Forecast, Price & News

-0.48 (-4.44 %)
(As of 05/10/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume855,462 shs
Average Volume1.94 million shs
Market Capitalization$1.97 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HIMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

Hims & Hers Health logo

About Hims & Hers Health

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Industry Household & Personal Products
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$1.97 billion
Next Earnings Date6/17/2021 (Estimated)


Overall MarketRank

1.05 out of 5 stars

Consumer Defensive Sector

16th out of 165 stocks

Household & Personal Products Industry

1st out of 24 stocks

Analyst Opinion: 4.1Community Rank: 1.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Hims & Hers Health (NYSE:HIMS) Frequently Asked Questions

Is Hims & Hers Health a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Hims & Hers Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIMS, but not buy additional shares or sell existing shares.
View analyst ratings for Hims & Hers Health
or view top-rated stocks.

What stocks does MarketBeat like better than Hims & Hers Health?

Wall Street analysts have given Hims & Hers Health a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hims & Hers Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hims & Hers Health?

Hims & Hers Health saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,660,000 shares, an increase of 71.9% from the March 15th total of 5,620,000 shares. Based on an average trading volume of 2,270,000 shares, the days-to-cover ratio is currently 4.3 days. Currently, 14.6% of the shares of the stock are short sold.
View Hims & Hers Health's Short Interest

When is Hims & Hers Health's next earnings date?

Hims & Hers Health is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Hims & Hers Health

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) released its quarterly earnings data on Wednesday, March, 17th. The company reported ($0.07) EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.09. The business earned $41.47 million during the quarter, compared to analyst estimates of $30.98 million.
View Hims & Hers Health's earnings history

What guidance has Hims & Hers Health issued on next quarter's earnings?

Hims & Hers Health updated its first quarter 2021 After-Hours earnings guidance on Thursday, March, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $48-50 million.

What price target have analysts set for HIMS?

7 analysts have issued 12-month price objectives for Hims & Hers Health's shares. Their forecasts range from $12.00 to $23.00. On average, they anticipate Hims & Hers Health's stock price to reach $16.20 in the next year. This suggests a possible upside of 57.0% from the stock's current price.
View analysts' price targets for Hims & Hers Health
or view top-rated stocks among Wall Street analysts.

Who are Hims & Hers Health's key executives?

Hims & Hers Health's management team includes the following people:
  • Mr. Andrew Dudum, Co-Founder, Chairman & CEO (Age 32, Pay $627.39k)
  • Mr. Spencer Lee, Chief Financial Officer (Age 42, Pay $537.6k)
  • Ms. Melissa Baird, Chief Operations Officer (Age 43, Pay $536k)
  • Ms. Soleil Teubner Boughton, Chief Legal Officer & Corp. Sec. (Age 42)
  • Dr. Patrick Carroll M.D., Chief Medical Officer (Age 63)
  • Ms. Leah S. Millheiser M.D., Sr. VP of Medical Affairs

Who are some of Hims & Hers Health's key competitors?

What is Hims & Hers Health's stock symbol?

Hims & Hers Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HIMS."

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.76%), Liberty Street Advisors Inc. (0.22%), Exos Asset Management LLC (0.02%), First National Trust Co (0.02%), Checchi Capital Advisers LLC (0.01%) and Signaturefd LLC (0.01%).

Which institutional investors are buying Hims & Hers Health stock?

HIMS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Liberty Street Advisors Inc., Exos Asset Management LLC, First National Trust Co, Checchi Capital Advisers LLC, Signaturefd LLC, GWM Advisors LLC, and Baldwin Brothers Inc. MA.

How do I buy shares of Hims & Hers Health?

Shares of HIMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hims & Hers Health's stock price today?

One share of HIMS stock can currently be purchased for approximately $10.32.

How much money does Hims & Hers Health make?

Hims & Hers Health has a market capitalization of $1.97 billion.

How many employees does Hims & Hers Health have?

Hims & Hers Health employs 181 workers across the globe.

What is Hims & Hers Health's official website?

The official website for Hims & Hers Health is www.forhims.com.

How can I contact Hims & Hers Health?

The company can be reached via phone at 800-368-0038.

This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.